Sonefpeglutide (LAPS GLP-2 analogue), a drug candidate from Hanmi Pharmaceutical, was granted to Eli Lilly under a licensing agreement announced on May 31, granting Eli Lilly exclusive worldwide rights (excluding South Korea) to develop, manufacture, and commercialize the drug. The…
On June 2, Everest Medicines announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, granting Travere exclusive development and commercialization rights for EVER001 (civorebrutinib) in all markets outside Greater China and certain countries in…
On June 3, Yunnan Baiyao announced that its Investigational New Drug (IND) application for INB301 Injection has received clearance from the U.S. Food and Drug Administration (FDA) to conduct clinical trials, with the proposed indication being cancer cachexia. According to…
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Dizal Pharmaceutical presented three latest research advances in non-small cell lung cancer (NSCLC), covering three products: Sunvozertinib (Sunvozertinib®), DZD6008, and Golidocitinib (Gaoreize®). Among these, the international multicenter Phase III…
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the landmark positive overall survival (OS) results from the Phase III HARMONi-6/AK112-306 study of Akeso’s global first-in-class PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as a…
On June 1, local time, Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for Camzyos (mavacamten) for the treatment of adolescent patients (aged 12 to under…
On June 1, local time, Amgen announced that the European Commission (EC) has approved its DLL3/CD3 bispecific antibody IMDYLLTRA® (tarlatamab) as a monotherapy for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have experienced disease…
Ciprofol Injection is a Category 1 intravenous anesthetic drug developed by Haisco with full independent intellectual property rights. In China, the drug was first approved for marketing in December 2020 and has since been approved for multiple indications, including sedation…
On June 2, 2026, Legend Biotech announced today that it will present, for the first time, preliminary clinical data for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy LB2501 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL) at…
Legend Biotech’s legendary status was first written by Carvykti (ciltacabtagene autoleucel). This BCMA CAR-T, licensed to Johnson & Johnson, has become the best-selling cell therapy product in the world. In 2025, Carvykti’s sales surged 95.05% to reach $1.887 billion, and…